AR114024A1 - PHARMACEUTICAL COMPOSITION, DOSAGE AND TREATMENT OF PH-POSITIVE LEUKEMIA - Google Patents

PHARMACEUTICAL COMPOSITION, DOSAGE AND TREATMENT OF PH-POSITIVE LEUKEMIA

Info

Publication number
AR114024A1
AR114024A1 ARP180103163A ARP180103163A AR114024A1 AR 114024 A1 AR114024 A1 AR 114024A1 AR P180103163 A ARP180103163 A AR P180103163A AR P180103163 A ARP180103163 A AR P180103163A AR 114024 A1 AR114024 A1 AR 114024A1
Authority
AR
Argentina
Prior art keywords
treatment
pharmaceutical composition
dosage
positive leukemia
leukemia
Prior art date
Application number
ARP180103163A
Other languages
Spanish (es)
Inventor
Fedor Nikolaevich Novikov
Germes Grigorievich Chilov
Original Assignee
Llc «Fusion Pharma»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llc «Fusion Pharma» filed Critical Llc «Fusion Pharma»
Publication of AR114024A1 publication Critical patent/AR114024A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Composición farmacéutica en forma de cápsulas para el tratamiento de la leucemia Ph⁺ caracterizada por la siguiente composición y relación de componentes, en % en masa: @@@@@@@@@Claim 1: Pharmaceutical composition in the form of capsules for the treatment of Ph⁺ leukemia characterized by the following composition and component ratio, in% by mass: @@@@@@@@@

ARP180103163A 2017-10-31 2018-10-31 PHARMACEUTICAL COMPOSITION, DOSAGE AND TREATMENT OF PH-POSITIVE LEUKEMIA AR114024A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017137972A RU2664420C1 (en) 2017-10-31 2017-10-31 Pharmaceutical composition, dosage and method of treatment ph+ leukemia

Publications (1)

Publication Number Publication Date
AR114024A1 true AR114024A1 (en) 2020-07-15

Family

ID=63177283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103163A AR114024A1 (en) 2017-10-31 2018-10-31 PHARMACEUTICAL COMPOSITION, DOSAGE AND TREATMENT OF PH-POSITIVE LEUKEMIA

Country Status (4)

Country Link
AR (1) AR114024A1 (en)
EA (1) EA201991811A1 (en)
RU (1) RU2664420C1 (en)
WO (1) WO2019088882A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477723C2 (en) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Protein kinase inhibitor (versions), use thereof for treating oncological diseases and based pharmaceutical composition
RU2652992C2 (en) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Novel crystalline salt form 3-(1,2,4-triazolo[4,3-a]pyridin-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl) benzamide for medical application

Also Published As

Publication number Publication date
WO2019088882A1 (en) 2019-05-09
EA201991811A1 (en) 2019-12-30
RU2664420C1 (en) 2018-08-17

Similar Documents

Publication Publication Date Title
CY1119566T1 (en) ANTIQUE RSV COMPOUNDS
SA517390583B1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MD4800C1 (en) Aminopyrimidinyl compounds as JAK inhibitors
MX2018007704A (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant.
DOP2016000208A (en) BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS
EA201790766A1 (en) NEW METHILPIPERIDINE CONNECTIONS SUITABLE FOR INHIBITING MICROSOMAL PROSTAGLANDIN-E2-SYNTHASE 1
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
CL2015002897A1 (en) Bace1 inhibitors
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
CY1123022T1 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING SITAGLIPTIN IN THE FORM OF IMMEDIATE RELEASE TABLETS
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
BR112017004580A2 (en) compound, pharmaceutical composition, combination product, use of a pharmaceutically acceptable compound or salt, and method of treatment.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
TR201717703A2 (en) APIXABAN FORMULATIONS
EA201892842A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
WO2016072692A3 (en) Composition for preventing or treating mucositis comprising necrox as effective ingredient
AR114024A1 (en) PHARMACEUTICAL COMPOSITION, DOSAGE AND TREATMENT OF PH-POSITIVE LEUKEMIA
MX2018004532A (en) Combination of trazodone and gabapentin for the treatment of pain.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
AR106203A1 (en) COMBINED THERAPY AND HCV TREATMENT REGIME